Henry Schein (NASDAQ:HSIC) Lifted to Strong-Buy at Baird R W

Baird R W upgraded shares of Henry Schein (NASDAQ:HSIC) from a hold rating to a strong-buy rating in a research note released on Monday morning, Zacks.com reports.

A number of other analysts have also recently weighed in on HSIC. Robert W. Baird upgraded shares of Henry Schein from a neutral rating to an outperform rating and boosted their price objective for the stock from $81.00 to $92.00 in a research note on Monday. UBS Group dropped their price objective on Henry Schein from $82.00 to $80.00 and set a neutral rating on the stock in a research note on Wednesday, May 8th. Barrington Research reaffirmed an outperform rating and issued a $92.00 target price on shares of Henry Schein in a report on Friday, July 5th. Piper Sandler reiterated an overweight rating and set a $86.00 price target on shares of Henry Schein in a report on Friday, June 21st. Finally, Evercore ISI lowered their price objective on shares of Henry Schein from $75.00 to $72.00 and set an in-line rating on the stock in a research note on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus target price of $81.67.

Henry Schein Price Performance

Shares of HSIC opened at $71.04 on Monday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.02 and a current ratio of 1.75. The firm has a market cap of $9.10 billion, a PE ratio of 24.00, a PEG ratio of 1.73 and a beta of 0.87. Henry Schein has a twelve month low of $60.01 and a twelve month high of $82.63. The firm’s 50 day moving average price is $68.20 and its 200 day moving average price is $71.90.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.21 billion. During the same period in the prior year, the company posted $1.21 earnings per share. Henry Schein’s revenue for the quarter was up 3.7% on a year-over-year basis. As a group, research analysts expect that Henry Schein will post 5.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of HSIC. McGlone Suttner Wealth Management Inc. bought a new position in Henry Schein in the fourth quarter valued at about $39,000. Beach Investment Counsel Inc. PA bought a new stake in shares of Henry Schein during the second quarter worth approximately $37,000. Blue Trust Inc. raised its stake in shares of Henry Schein by 104.2% during the second quarter. Blue Trust Inc. now owns 931 shares of the company’s stock worth $60,000 after buying an additional 475 shares during the last quarter. Mather Group LLC. bought a new position in Henry Schein in the first quarter valued at approximately $97,000. Finally, Palisade Asset Management LLC bought a new stake in shares of Henry Schein during the 1st quarter valued at $113,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.